IPP Bureau
Modis and ValGenesis partner to bring Best-in-Class validation processes to Italian pharma
By IPP Bureau - February 18, 2022
The partnership will help digitize and automate existing tasks traditionally managed on paper, significantly reducing costs and lead times while increasing compliance
Health Canada authorizes Novavax Covid-19 vaccine
By IPP Bureau - February 18, 2022
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Canada
Sandoz launches generic lenalidomide in 19 countries across Europe
By IPP Bureau - February 18, 2022
Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines
Quotient Sciences integrates drug substance into Translational Pharmaceutics Platform
By IPP Bureau - February 18, 2022
The newly enhanced drug development platform will help empower innovators with the fastest development timelines
Ribon Therapeutics appoints Prakash Raman as President and CEO
By IPP Bureau - February 18, 2022
Dr. Raman has succeeded Victoria Richon
Evonik invests in start-up to improve patient recovery after open-chest surgery
By IPP Bureau - February 18, 2022
Evonik invests in start-up to improve patient recovery after open-chest surgery
Medicx Health elevates Virginia Evans to Sr. VP
By IPP Bureau - February 18, 2022
Virginia will be responsible for meeting client needs for both media and commercial analytics.
Lyra Therapeutics appoints Harlan W. Waksal as Executive Chairman
By IPP Bureau - February 18, 2022
Waksal holds a successful track record of founding, scaling and advising growth-oriented companies.
Agilent acquires Virtual Control’s AI technology to enhance lab productivity
By IPP Bureau - February 18, 2022
Agilent will integrate the technology into its lab informatics platforms, enabling customers to automate GC/MS data analysis
Bayer raises peak sales for Nubeqa to exceed €3 billion
By IPP Bureau - February 18, 2022
Darolutamide is developed jointly by Bayer and Orion Corporation
Ligand posts strong 2021 performance
By IPP Bureau - February 18, 2022
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
AptarGroup reported 2021 sales at US $3.23 billion
By IPP Bureau - February 18, 2022
AptarGroup acquired Voluntis and 80% of Weihai Hengyu Medical Products in 2021.
LEO Pharma appoints Brian Hilberdink President of LEO Pharma, US
By IPP Bureau - February 18, 2022
Brian joins LEO Pharma from Novo Nordisk, U.S. where he served as Senior Vice President of Sales.
Moderna’s Covid-19 vaccine approved in Australia for children (6-11 years)
By IPP Bureau - February 17, 2022
Moderna's vaccine has already received regulatory approval for adults and adolescents in Australia
IPP to organize e-conference on 'Indian Pharma Industry: Developing a conducive ecosystem' on Feb 18
By IPP Bureau - February 17, 2022
The speakers for the e-conference are: Dr. Mukund Chorgade, President/CSO, THINQ Pharma; Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance; Jayaseelan J., National Vice President (Industry Division), Indian Pharmaceutical Association; Spandan Mishra who is Director- Sales, Customer Service & Logistics for Evonik India, Nepal & Sri Lanka region; Dr. Kommu Nagaiah, Chief Scientist & Head, CSIR-IICT; Govind K. Jaju, Partner, Suingora Consulting; nd Pravin Prashant, Executive Editor, Indian Pharma Post & Editor, Indian Chemical News.
